| Code | CSB-RA011649MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Basiliximab, specifically targeting IL2RA (CD25), the alpha chain of the interleukin-2 receptor. IL2RA is expressed primarily on activated T lymphocytes and plays a critical role in T cell proliferation and immune response regulation. Upon IL-2 binding, IL2RA combines with IL2RB and IL2RG to form a high-affinity receptor complex that triggers T cell activation and clonal expansion. Aberrant IL2RA expression is associated with various autoimmune disorders, transplant rejection, and certain hematological malignancies, including adult T-cell leukemia and some lymphomas.
Basiliximab is a clinically established chimeric mouse-human monoclonal antibody used therapeutically as an immunosuppressant to prevent acute organ rejection in transplant recipients. This research-grade biosimilar provides investigators with a valuable tool for studying IL-2 receptor signaling pathways, T cell activation mechanisms, immune regulation, and transplantation immunology. It enables exploration of therapeutic strategies targeting IL2RA in autoimmune diseases and cancer research, facilitating both in vitro and in vivo immunological studies.
There are currently no reviews for this product.